Bezafibrate treatment rescues neurodevelopmental and neurodegenerative defects in 3D cortical organoid model of MAPT frontotemporal dementia
Bezafibrat-Behandlung behebt neuroentwicklungs- und neurodegenerative Defekte in einem 3D-Kortikalorganoid-Modell der MAPT-Frontotemporaldemenz
Alzheimer's & Dementia · 2025-08 · 21 (8)
DOI: 10.1002/alz.70419 ↗Auf einen Blick
In einem 3D-Kortikalorganoid-Modell führte die MAPT-IVS10+16-Mutation zu Störungen der neuronalen Entwicklung und Funktion. Bezafibrat stellte mitochondriale Parameter, Synapsenfunktion und Tau-Physiologie wieder her.
Fragestellung
Welchen Einfluss hat die MAPT-IVS10+16-Mutation auf kortikale Organoide, und kann Bezafibrat die dadurch ausgelösten Defekte abschwächen?
Methode
Patterned kortikale Organoide aus isogenen kontroll- und mutierten humanen iPSC-Linien; Analyse mit Nanostring-Genexpression, Immunfluoreszenz und Calcium-Imaging.
Ergebnisse
Die Tau-mutierten Organoide zeigten veränderte mitochondriale Funktion, veränderte Genexpression zur neuronalen Entwicklung sowie reduzierte synaptische Marker und neuronale Aktivität. Bezafibrat restaurierte den Mitochondriengehalt und verbesserte Synapsenfunktion und Tau-Physiologie.
Schlussfolgerung der Autor:innen
Die Autor:innen folgern, dass eine gezielte Beeinflussung der mitochondrialen Funktion mit Bezafibrat tauinduzierte neuroentwicklungsbedingte Defizite rückgängig machen könnte.
Kernaussagen
- MAPT-IVS10+16 störte kortikale Differenzierung und synaptische Reifung.
- Tau-mutierte Organoide zeigten Mitochondriendysfunktion und Tau-Hyperphosphorylierung.
- Bezafibrat normalisierte mitochondriale Parameter und Netzwerfunktion.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 14.08.2025. Verfasst von Federica Cordella und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology "V. Erspamer" and Center for Research in Neurobiology "Daniel Bovet", Sapienza University of Rome, Roma, It…. Hauptthemen laut MEDLINE: Bezafibrate, tau Proteins, Organoids, Frontotemporal Dementia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: D-Tails-IIT Joint Lab, Sapienza University grants, Progetto ECS 0000024 Rome Technopole.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION The intronic MAPT mutation IVS10+16 is linked to familial frontotemporal dementia, causing hyperphosphorylation and accumulation of tau protein, resulting in synaptic and neuronal loss and neuroinflammation in patients. This mutation disrupts MAPT gene splicing, increasing exon 10 inclusion and leading to an imbalance of 3R and 4R Tau isoforms. METHODS We generated patterned cortical organoids from isogenic control and mutant human induced pluripotent stem cell (iPSC) lines. Nanostring gene expression analysis, immunofluorescence, and calcium imaging recordings were used to study the impact of the MAPT IVS10+16 mutation on neuronal development and function. RESULTS Tau mutant cortical organoids showed altered mitochondrial function and gene expression related to neuronal development, with synaptic markers and neuronal activity reduction. Bezafibrate treatment restored mitochondrial content and rescued synaptic functionality and tau physiology. DISCUSSION These findings suggest that targeting mitochondrial function with bezafibrate could potentially reverse tau‐induced neurodevelopmental deficits, highlighting its therapeutic potential for tauopathies like frontotemporal dementia. Highlights The IVS 10+16 MAPT mutation significantly disrupts cortical differentiation and synaptic maturation, evidenced by downregulated genes associated with synapses and neuronal development. Tau‐mutant cortical organoids exhibit mitochondrial dysfunction, with fewer and smaller mitochondria alongside tau hyperphosphorylation and aggregation, which further contribute to neuronal damage and disease progression. Treatment with bezafibrate effectively normalizes mitochondrial parameters, enhances neuronal integrity and synaptic maturation, and restores network functionality, showcasing its promise as a therapeutic strategy for tauopathies. The 3D in vitro disease model used in this study proves valuable for studying tauopathies and testing new drugs, effectively mimicking key aspects of tau‐related neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Pharmacology "V. Erspamer" and Center for Research in Neurobiology "Daniel Bovet", Sapienza University of Rome, Roma, Italy.
- Center for Life Nano- & Neuro-Science, Istituto Italiano di Tecnologia, Roma, Italy.
- Department of Molecular Medicine, Sapienza University of Rome, Roma, Italy.
- Department of Experimental Medicine, Sapienza University of Rome, Roma, Italy.
- Department of Fundamental Neurosciences, University of Lausanne, Lausanne, Switzerland.
- D-Tails Research srl BC, Rome, Italy.
ORCID-Profile: Federica Cordella, Lorenza Mautone, Debora Salerno, Silvia Ghirga, Chiara D'Antoni, Maria Anele Romeo, Mara Cirone, Paola Bezzi, Silvia Di Angelantonio
Förderung
- D-Tails-IIT Joint Lab
- Sapienza University grants
- Progetto ECS 0000024 Rome Technopole
- PNRR Missione 4 Componente 2 Investimento 1.5
- Italian Ministry of Health (MoH) Alternative Methods to Animal Testing Grant 2023
- ERANET-Neuron SNSF
- Synapsis Foundation Switzerland
- ERA-NET Neuron
Zitieren
APA
Cordella, F., Mautone, L., Salerno, D., Tondo, L., Ghirga, S., D'Antoni, C., Parente, E., Romeo, M. A., Cirone, M., Bezzi, P., & Di Angelantonio, S. (2025). Bezafibrate treatment rescues neurodevelopmental and neurodegenerative defects in 3D cortical organoid model of MAPT frontotemporal dementia. Alzheimer's & Dementia, 21(8). https://doi.org/10.1002/alz.70419
Vancouver
Cordella F, Mautone L, Salerno D, Tondo L, Ghirga S, D'Antoni C, et al. Bezafibrate treatment rescues neurodevelopmental and neurodegenerative defects in 3D cortical organoid model of MAPT frontotemporal dementia. Alzheimer's & Dementia. 2025;21(8). doi:10.1002/alz.70419
BibTeX
@article{Cordella2025,
author = {Cordella, Federica and Mautone, Lorenza and Salerno, Debora and Tondo, Lucrezia and Ghirga, Silvia and D'Antoni, Chiara and Parente, Erika and Romeo, Maria Anele and Cirone, Mara and Bezzi, Paola and Di Angelantonio, Silvia},
title = {Bezafibrate treatment rescues neurodevelopmental and neurodegenerative defects in 3D cortical organoid model of MAPT frontotemporal dementia},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {8},
doi = {10.1002/alz.70419}
}
EUVIMED